<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751606</url>
  </required_header>
  <id_info>
    <org_study_id>7TNANO1</org_study_id>
    <nct_id>NCT02751606</nct_id>
  </id_info>
  <brief_title>Nano MRI on 7 Tesla in Rectal and Breast Cancer</brief_title>
  <official_title>Nano MRI on 7 Tesla: a Technical Validation Study in Rectal and Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the diagnostic accuracy of an USPIO contrast agent (ferumoxtran-10) in&#xD;
      combination with 7 Tesla MRI to detect lymph node metastases in rectal and breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Presence of lymph node metastases in cancer is a key factor for determining prognosis and&#xD;
      forming an adequate treatment plan. Determining lymph node status, however, is a challenge.&#xD;
      Ferumoxtran-10, an ultrasmall superparamagnetic iron oxide (USPIO) particle has proven to be&#xD;
      a valuable contrast agent for detecting lymph node metastases using magnetic resonance&#xD;
      imaging (MRI) in various types of cancer (also called nano-MRI). For small lymph node&#xD;
      metastases (&lt;5mm) the diagnostic accuracy of this technique does, however, drop&#xD;
      substantially. Most of the studies that have been performed with these particles used a 1.5&#xD;
      Tesla or 3 Tesla MRI scanner. The investigators would like to increase the resolution of&#xD;
      nano-MRI by using a 7 Tesla scanner, such that the investigators can increase the sensitivity&#xD;
      of this technique for small lymph nodes. With this study the investigators would like to&#xD;
      validate the results of this technique with pathology in rectal and breast cancer. In these&#xD;
      cancer types many patients undergo a surgical lymph node dissection by bulk excision of&#xD;
      tissue including the nodes, enabling a node-to-node comparison between MRI and pathology to&#xD;
      validate our nano-MRI results . If successful this technique would form a non-invasive&#xD;
      alternative to the current lymph node staging techniques such as surgery. Additionally (if&#xD;
      metastatic nodes are present), it could complement image guided focal therapies on lymph node&#xD;
      metastases such as radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.</measure>
    <time_frame>within 2 weeks prior to the patients surgery</time_frame>
    <description>The images of the 7 Tesla MRI scan will be evaluated by a radiologist and every lymph node that is found will be scored as positive or negative. This will be compared to the pathological results to determine the sensitivity and specificity of ferumoxtran enhanced MRI on 7 Tesla for diagnosing whether a lymph node is metastatic or not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of 7 Tesla and 3 Tesla MRI</measure>
    <time_frame>within 2 weeks prior to the patients surgery</time_frame>
    <description>The diagnostic accuracy (sensitivity and specificity as described in outcome 1) of 3 Tesla and 7 Tesla will be compared</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rectal Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Breast and rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferumoxtran-10</intervention_name>
    <description>ferumoxtran-10 will be administered intravenously one day prior to the MRI scan</description>
    <arm_group_label>Breast and rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7 Tesla MRI</intervention_name>
    <description>Subjects undergo a 7 Tesla MRI scan</description>
    <arm_group_label>Breast and rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3 Tesla MRI</intervention_name>
    <description>Subjects undergo a 3 Tesla MRI scan</description>
    <arm_group_label>Breast and rectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Inclusion criteria rectal cancer patients:&#xD;
&#xD;
          -  Patients with recently histologically proven rectal cancer, who are planned to undergo&#xD;
             a total mesorectal excision without neo-adjuvant radiotherapy.&#xD;
&#xD;
        Inclusion criteria breast cancer patients:&#xD;
&#xD;
          -  Patients with recently histologically proven breast cancer (Stage II), who are planned&#xD;
             for surgery with sentinel node procedure, but will receive no neo-adjuvant therapy or&#xD;
             will undergo an axillary lymph node dissection without prior sentinel node procedure&#xD;
             and will receive no neo-adjuvant therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General exclusion criteria:&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Karnofsky score &lt;= 70&#xD;
&#xD;
          -  Contraindications for 7T MRI:&#xD;
&#xD;
               -  Epilepsy&#xD;
&#xD;
               -  Inability to provide informed consent&#xD;
&#xD;
               -  Metal implants that are not compatible with 7 Tesla MRI&#xD;
&#xD;
          -  Contraindications to USPIO based contrast agents:&#xD;
&#xD;
               -  prior allergic reaction to ferumoxtran-10 or any other iron preparation&#xD;
&#xD;
               -  prior allergic reaction contributed to dextran or other polysaccharide, in any&#xD;
                  preparation&#xD;
&#xD;
               -  prior allergic reaction to contrast media of any type&#xD;
&#xD;
               -  hereditary hemochromatosis, thalassemia, sickle cell anemia;&#xD;
&#xD;
        Exclusion criteria for rectal cancer:&#xD;
&#xD;
          -  Inflammatory diseases of the abdomen (such as Crohn's disease)&#xD;
&#xD;
          -  Previous abdominal surgery or radiotherapy&#xD;
&#xD;
        Exclusion criteria for breast cancer:&#xD;
&#xD;
          -  Prior radiotherapy or surgery to axillae&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Scheenen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboudumc Nijmegen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Philips, MD</last_name>
    <phone>+31 24 36 68392</phone>
    <email>Bart.Philips@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Philips, MD</last_name>
      <phone>0631961348</phone>
      <email>bartphilips1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tom Scheenen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferumoxtran</keyword>
  <keyword>MRI Scans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

